Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
Walmart announced on Tuesday that it’s introducing a new same-day delivery service for prescription medication.
The leadership change comes as the retail pharmacy industry faces thin profit margins, store closures, and layoffs.
A new study suggests increasingly popular GLP-1 drugs could help cut opioid and alcohol abuse nearly in half.
Bausch + Lomb has stirred up significant interest from the pair of private equity giants, TPG and Blackstone.
A single point of software failure can turn entire industries into teetering Jenga towers. Next time could be a lot worse.
UnitedHealth, CVS, and Cigna want FTC chair Lina Khan and two other officials recused from their case due to alleged biases.
Obesity drugmaker Rivus is working with banks to complete a US public listing that could happen before the end of the year.
Amazon’s patent to help doctors take better notes highlights the company’s massive bet on the healthcare space.
Dallas-based Steward Health Care is may just well be the poster child for private equity investment in healthcare gone wrong.
The insurance industry needs to be careful when using AI, or else AI black boxes could render consumers uninsurable without any explanation.
Moderna walked a tightrope trying to convince shareholders it can both develop a new portfolio of drugs and keep costs down in the process.
AI has a lot of promise in the healthcare industry in areas such as documentation, imaging, and quicker diagnostics as staffing shortages loom.
Philips’ latest patent could predict how long you’ll be in the waiting room.
The World Health Organization has declared mpox to be a public health emergency, and pharmaceutical and healthcare winners have emerged.
WW announced on Thursday that it will be laying off employees and cutting costs to the tune of $100 million per year.
A patent for generative neural network-based ultrasounds from medical device firm Philips could provide more data to develop AI innovations throughout…
Pfizer, Moderna, and GlaxoSmithKline are developing vaccines for RSV to fill the gap on their balance sheets.